A new nanoparticle-based vaccine has demonstrated success in ferret models of COVID-19, inducing strong neutralising antibodies against SARS-CoV-2.
List view / Grid view
Filter the results
A novel in silico approach applied to drug screening has revealed three potential candidates that may interact with multiple proteins of SARS‐CoV‐2.
A new study has suggested that asymptomatic individuals with COVID-19 mount an efficient T-cell response that protects the host.
Researchers have developed a new screening technique called biological activity-based modelling to identify drug candidates.
DTR's Victoria Rees interviews Payton Weidenbacher from Stanford University, who discusses a new potential SARS-CoV-2 vaccine that the team he works on developed using nanotechnology.
Researchers have used computer simulations to model how the SARS-CoV-2 fusion peptide interacts with and penetrates the cell membrane.
Researchers have developed stem cell-derived organoids to reveal how SARS-CoV-2 interacts with lung and brain cells differently.
Between January and October 2020, scientists globally have published more than 87,000 papers about the coronavirus.
Vascor (bepridil) could be used to treat COVID-19, according to a new study which screened drugs to repurpose against SARS-CoV-2.
Researchers have found that the S1/S2 cleavage of the SARS-CoV-2 Spike protein could be a potential target for COVID-19 therapeutics.
The UK Government will give £18.5 million in funding to four studies researching the causes and potential treatments of long COVID.
A study has shown the D614G mutation in the Spike protein of SARS-CoV-2 makes the coronavirus more transmissible than the original virus from China.
A peptide administered to ferrets protected them from SARS-CoV-2 viral transmission when housed with infected ferrets.
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.